Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic
  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

  • Buntanetap is designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43
  • The study demonstrated significant efficacy and safety for buntanetap in a subgroup of early Alzheimer’s patients in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a recognized genetic factor linked to Alzheimer’s
  • Annovis Bio has been selected to present detailed data from its Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024

June is Alzheimer’s & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer’s disease and other forms of dementia, as well as the importance of brain health. Even though the month is almost over, Annovis Bio’s commitment to the Alzheimer’s community goes on.

Annovis Bio (NYSE: ANVS), a late-stage drug platform company, recently announced promising results from its Phase II/III study on buntanetap, a drug candidate aimed at treating neurodegenerative diseases like Alzheimer’s (“AD”) and Parkinson’s diseases (“PD”). The study demonstrated significant efficacy and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.